Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

The oncofetal protein IMP3: a novel biomarker and triage tool for premalignant atypical endometriotic lesions.

Vercellini P, Cribiù FM, Del Gobbo A, Carcangiu ML, Somigliana E, Bòsari S.

Fertil Steril. 2013 Jun;99(7):1974-9. doi: 10.1016/j.fertnstert.2013.02.002. Epub 2013 Mar 7.

PMID:
23473990
2.

Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?

Samartzis EP, Samartzis N, Noske A, Fedier A, Caduff R, Dedes KJ, Fink D, Imesch P.

Mod Pathol. 2012 Jun;25(6):885-92. doi: 10.1038/modpathol.2011.217. Epub 2012 Feb 3.

3.

The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.

Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z.

Am J Surg Pathol. 2008 Feb;32(2):304-15. doi: 10.1097/PAS.0b013e3181483ff8.

PMID:
18223334
4.

IMP3 can predict aggressive behaviour of lung adenocarcinoma.

Beljan Perak R, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V, Peric M.

Diagn Pathol. 2012 Nov 28;7:165. doi: 10.1186/1746-1596-7-165.

5.

The utility of PAX8 and IMP3 immunohistochemical stains in the differential diagnosis of benign, premalignant, and malignant endocervical glandular lesions.

Danialan R, Assaad M, Burghardt J, Newcomb P, Cartun RW, Mandavilli S.

Gynecol Oncol. 2013 Aug;130(2):383-8. doi: 10.1016/j.ygyno.2013.04.020. Epub 2013 Apr 23.

PMID:
23618832
6.
7.

S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy.

Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL.

Hum Pathol. 2010 Sep;41(9):1210-9. doi: 10.1016/j.humpath.2010.01.014. Epub 2010 Apr 10.

PMID:
20382408
8.

IMP3 is a novel biomarker to predict metastasis and prognosis of tongue squamous cell carcinoma.

Li HG, Han JJ, Huang ZQ, Wang L, Chen WL, Shen XM.

J Craniofac Surg. 2011 Nov;22(6):2022-5. doi: 10.1097/SCS.0b013e3182319750.

PMID:
22067851
9.

Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.

Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P, Kalir T.

Cancer. 2002 Jun 1;94(11):2935-40.

10.

Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.

Shi M, Fraire AE, Chu P, Cornejo K, Woda BA, Dresser K, Rock KL, Jiang Z.

Am J Surg Pathol. 2011 Jun;35(6):878-82. doi: 10.1097/PAS.0b013e318218985b.

PMID:
21566519
11.

Immunohistochemical evaluation of epithelial antigen Ber-Ep4 and CD10: new markers for endometriosis?

Capobianco G, Wenger JM, Marras V, Cosmi E, Ambrosini G, Dessole M, Cherchi PL.

Eur J Gynaecol Oncol. 2013;34(3):254-6.

PMID:
23967557
12.

Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa.

Strehl JD, Hoegel J, Hornicek I, Hartmann A, Riener MO.

Int J Clin Exp Pathol. 2014 Apr 15;7(5):2091-101. eCollection 2014.

13.

Comparative immunohistochemical studies of endometriosis lesions and endometriotic cysts.

Nezhat FR, Kalir T.

Fertil Steril. 2002 Oct;78(4):820-4.

PMID:
12372462
14.

Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2012 Jan;25(1):122-30. doi: 10.1038/modpathol.2011.143. Epub 2011 Oct 7.

15.

Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.

Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, Fischer AH.

Mod Pathol. 2007 Dec;20(12):1263-8. Epub 2007 Sep 21.

16.

Transmembrane estrogen receptor GPR30 is more frequently expressed in malignant than benign ovarian endometriotic cysts and correlates with MMP-9 expression.

Long L, Cao Y, Tang LD.

Int J Gynecol Cancer. 2012 May;22(4):539-45. doi: 10.1097/IGC.0b013e318247323d.

PMID:
22495744
17.

IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study.

Wang L, Li HG, Xia ZS, Lü J, Peng TS.

Chin Med J (Engl). 2010 Dec;123(24):3554-8.

18.

Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis.

Kobayashi H.

Int J Clin Oncol. 2009 Oct;14(5):378-82. doi: 10.1007/s10147-009-0931-2. Epub 2009 Oct 25. Review.

PMID:
19856043
19.

Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma.

Cornejo K, Shi M, Jiang Z.

Hum Pathol. 2012 Oct;43(10):1567-72. doi: 10.1016/j.humpath.2011.12.020. Epub 2012 Apr 10.

PMID:
22497850
20.
Items per page

Supplemental Content

Write to the Help Desk